Orchid Pharma Limited has informed the Exchange regarding 'Intimation related to the Scheme of Amalgamation of DhanukaLaboratories Limited ( Amalgamating Company ) with Orchid PharmaLimited ( Amalgamated Company/Company ) and their respectiveshareholders and creditors ( the Scheme ) under Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015'.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Orchid Pharma has filed a Joint Second Motion Petition with the NCLT Chennai Bench on July 9, 2025, as the next step in the proposed amalgamation of Dhanuka Laboratories Limited into Orchid Pharma Limited. This filing follows an earlier intimation dated June 26, 2025 regarding the NCLT-convened meeting of Orchid Pharma's equity shareholders, who had approved the scheme. The amalgamation, once cleared, will see Dhanuka Laboratories merge into Orchid Pharma with the combined entity's shareholders and creditors becoming part of the amalgamated company.
Shareholders should note this is a procedural milestone in the NCLT approval process for the merger, not a final approval. If the scheme is sanctioned, it could expand Orchid Pharma's scale and business scope, but the actual benefits and any share-swap ratio will only become clear once the NCLT order is issued.